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| INTRODUC TI ON
Gastric adenocarcinoma (GAC) is the main histopathological type of gastric cancer (GC). Gastric cancer is the main leading cause of cancer-related death worldwide. In 2012, more than 950 000 new GC cases were reported and 723 000 deaths occurred.
1 High mortality rates have been reported in East Asia, including China, Japan, and Korea. 2, 3 This is mostly as a result of detection at an advanced stage. Less than 20% of cases are detected at a localized stage and the 5-year survival rate of these cases is approximately 75%. 4 Early detection of GC is hampered by a lack of specific symptoms before it has spread beyond the original site and the lack of reliable noninvasive screening tests.
Currently, the diagnosis of GC is based on endoscopic examina- and CyclinB1) for early detection of patients with gastric cardia adenocarcinoma (GCA), and also reported that a combination of multiple autoantibodies to TAAs might be helpful in distinguishing GCA patients from normal individuals. Their study suggested that a larger sample size of GCA patients and a panel of multiple TAAs might improve the sensitivity and specificity in GCA detection. Our previous study created and evaluated a logistic regression model (a panel of six TAAs) to predict the risk of diagnosis with GC in a training cohort (n = 558) and in a validation cohort (n = 372). 14 The predictive model showed good diagnostic performance of GC with AUC of 0.841 in the training cohort and 0.856 in the validation cohort.
On the basis of the previous study, 14 we further explored the   diagnostic value of 14 antibodies (p53, p62, c-Myc, PTEN, ENO1,   HSPD1, p16, HCC1.4, NPM1, 14-3-3zeta, MDM2, Cyclin B1, IMP1, and RalA) in GAC, and the association of these anti-TAA and clinical characteristics, including tumor stage, tumor size, differentiation degree, and lymphatic metastasis. Recursive partitioning approach (RPA) was used to customize an optimal panel from 14 TAAs. In addition, the prognostic role of autoantibodies in GAC patients was also explored.
| MATERIAL S AND ME THODS

| Patients and serum samples
In the present study, a case-control study was designed. 
| Detection of 14 anti-TAA autoantibodies by ELISA
All of the recombinant TAA proteins in the present study, including p53, p62/IMP2, c-Myc, PTEN, ENO1, HSPD1, p16, HCC1.4, NPM1, 14-3-3zeta, MDM2, Cyclin B1, IMP1, and RalA, were expressed and purified through the prokaryotic expression system in our laboratory.
All sera were collected and stored at −80°C. Autoantibodies against 14 TAAs were detected in serum samples by ELISA, which was described in detail in our previous study. 14 In brief, purified proteins were coated onto 96-well microliter plates at a concentration of 0.5 μg/mL and 100 μL/well. 
| Statistical analysis
All statistical analyses were carried out using Prism software TA B L E 1 Characteristics of GAC patients and normal individuals in the current study 11.4.2.0). Areas under curves (AUC), sensitivity, and specificity were used to evaluate the diagnostic performance of all anti-TAA antibodies. All statistical tests are two-tailed. P < .05 was considered as significant difference and vice versa in all statistical analyses.
Recursive partitioning approach was used in the current study to select optimal TAA for GAC detection. RPA is a multivariate and nonparametric statistical methodology, 15, 16 the algorithm of which is simple and intuitive. In brief, the recursive partitioning program determines every variable's cutoff point (the titer of each of the 14 antibodies), which optimally splits all subjects into cancer and normal and, finally, selects the variable that performs best.
Then, it repeats the process on every variable until no additional partitioning is warranted. 17 RPART software package which was implemented in R (version 3.4.3; Mathsoft) 18 was used to generate the decision trees depicting the classification rules generated through recursive partitioning. To correct overtraining, the trees were pruned using the 1 SE rule described by Breiman. and (v) the cutoff is chosen while Youden's index is the highest. Data of dichotomous variables were then analyzed using RPA.
In addition, the overall survival curves of the patients positive for autoantibodies in the panel of nine anti-TAA were generated by SPSS 21.0
| RE SULTS
| Characteristics of study subjects
In total, 407 GAC patients and 407 normal controls were included in the case-control study. In addition, 25 GAC patients who had received gastrectomy treatment only were included and followed up for approximately 10 months to observe the titers of anti-TAA autoantibodies after tumor resection. Detailed characteristics of all subjects are shown in Table 1 . There were no significant differences of age and gender between the case group and the control group (P > .05), but the GAC group showed a higher frequency of family cancer history compared with that in the control group (P < .05).
| Performance of single autoantibody to each of 14 TAAs in the diagnosis of GAC
The 14 recombinant TAA proteins (p53, p62/IMP2, c-Myc, PTEN, ENO1, HSPD1, p16, HCC1.4, NPM1, 14-3-3zeta, MDM2, CyclinB1, IMP1, and RalA) were used as antigens to detect the corresponding autoantibody in 407 GAC sera and 407 normal human sera by ELISA. Figure 1 shows that it was obvious that antibodies to certain TAA proved useful for distinguishing GAC from NHS. All anti-TAA autoantibodies showed higher titers in GAC cases compared to controls except anti-RalA and anti-IMP1 antibodies.
Receiver operating characteristic curves were generated to evaluate the diagnostic value of a single anti-TAA antibody in GAC.
Detailed information is shown in Figure 2 However, anti-IMP1 antibodies showed low AUC of 0.507 (P > .05).
The results showed that a single antibody with a sensitivity of 33.17%
could not be used in the diagnosis of GAC. Studies showed that the F I G U R E 1 Levels (optical density, OD) of antibodies to 14 tumorassociated antigens (TAAs) in the gastric adenocarcinoma (GAC) and normal human sera (NHS) groups. Line and "+" within a box mark the median and mean, respectively. Whiskers mark 5-95 percentiles. NHS (N = 407); GAC (N = 407). *P < .0036 (Wilcoxon matchedpairs signed rank test) showed that the average OD value was significantly higher in GAC sera than in NHS combination of multiple TAAs can improve the diagnostic performance of cancer. [20] [21] [22] However, it is problematic to customize a panel of TAAs. RPA was used to find optimal subsets of the 14 antigen-antibody panel to distinguish cancer patients from normal individuals.
| Classification trees
Classification trees are shown in Figure 3B -F follow the same principle as that described for GAC ( Figure 3A ).
The trees associated with five cutoff standards were consistent and had the same node (anti-p16 antibody). c-Myc also appeared in five of six trees and is the first determinant in four trees. Interestingly, Figure 3B ,C shows that trees consist of four antibodies to the same antigens (c-Myc, MDM2, p16, 14-3-3zeta). In addition, antibodies to MDM2, p16 and 14-3-3zeta also appear in Figure 3E . Figure 4 shows the ROC of these six trees. The AUC of the original OD tree was 0.857 (P < .05), the highest among six trees ( Figure 4A) . Also, the AUCs vary as the cutoffs vary. The AUC of the mean + 2SD tree was 0.667, more than that of the mean + 1SD tree and the mean + 3SD
tree. Also, the AUCs of the mean plus SD trees ( Figure 4D -F) were less than those of the other two trees ( Figure 4B ,C), which were 0.717 and 0.690, respectively.
| Association of antibodies to nine TAA with clinical characteristics of GAC
The first participation tree showed the highest performance in the diagnosis of GAC among the six trees, which consisted of anti-TAA 
| Prognostic performance of antibodies against nine TAA in patients with GAC
We followed up the 407 GAC patients for 36 months and obtained their outcomes (death from GAC or survival). All GAC patients were divided into autoantibody-positive and -negative groups based on nine antibodies, and survival rates of these two groups were evaluated and showed no differences ( Figure 7A ). All GAC patients were also divided into patients with two or more positive autoantibodies and patients with one positive autoantibody or all negative autoantibodies based on nine antibodies and survival rates were also evaluated. The results showed that GAC patients positive for two or more autoantibodies had a worse prognosis than that of the group with patients positive for no or one antibody ( Figure 7B ). 
F I G U R E 3 Classification trees for gastric adenocarcinoma (GAC) on the basis of recursive partitioning analysis. A, Original optical density (OD). B, The cutoff is chosen when the
F I G U R E 5
Positive rates of nine antibodies in gastric adenocarcinoma (GAC) patients and normal human sera (NHS). A, The cutoff is chosen when the sensitivity is the highest, while specificity is >90%. Chi-squared test was used to compare the frequency between case and control groups. B, Receiver operating characteristic (ROC) curve of the panel of nine tumor-associated antigens (TAA) in the diagnosis of GAC based on logistic regression. *P < .05; **P < .01.
| Titers of antibodies against 14 TAA in serial sera before and after cancer resection
A total of 67 serial serum samples from 25 GAC patients collected before and after cancer resection were analyzed to investigate the temporal changes of these 14 autoantibodies. The cutoff value was chosen while the Youden index was the largest, and the specificity was more than 90%. Figure 8 shows the temporal changes for some autoantibodies with significant changes in sera from 25 GAC patients before and after cancer resection. Interestingly, several antibodies showed a significant rise in many patients after resection. For example, in patient 1 that donated two sera, one month before resection F I G U R E 6 Diagnostic performances of antibodies to nine tumor-associated antigens (TAAs) in the subgroups of gastric adenocarcinoma (GAC) patients based on tumor stage, differentiation, tumor size and lymphatic metastasis. A-D, the ROCs of autoantibodies in subgroups of GAC compared to NHS. E-H, the positive rates of autoantibodies in subgroups of GAC. Chi-squared tests showed no difference between the subgroups among the 14 antibodies. AUC, area under the curve and nine months after resection, the levels of antibodies against p53, p62/IMP2, c-Myc, PTEN, ENO1, HCC1.4, NPM1, 14-3-3zeta, IMP1, and RalA showed an increase from negative status to positive status after resection whereas anti-CyclinB1, p16, HSPD1, and MDM2 antibody showed no significant difference (Figure 8 ). In addition, if a single GAC patient had more than one serum before and after surgery, the means of OD values from the sera before resection and after resection were calculated, respectively. Figure 9 shows that the levels of 10 antibodies were significantly higher in patients after resection than before resection, including ENO1, PTEN, p62/IMP2, NPM1, HCC1.4, HSPD1, IMP1, c-Myc, RalA, and 14-3-3zeta antibodies, whereas other four antibodies against CyclinB1, p53, p16, and MDM2 showed no significant difference (P > .05).
| D ISCUSS I ON
We detected antibodies against 14 TAAs in 407 GAC sera and in 407 NHS using ELISA. Of these TAAs, c-Myc, p62/IMP2, 14-3-3zeta, MDM2 and IMP1 are oncogene products, [23] [24] [25] [26] [27] and PTEN, p16, p53, 52.0% and a specificity of 90.5% in GC, and was also observed to
Comparison of autoantibody serum levels to 14 tumor-associated antigens in serial serum samples before and after resection for gastric adenocarcinoma patients. The line within a box marks the mean OD of a single antibody in sera before or after resection. Floating bars are from min to max. *P < .01
have no significant differences based on depth of tumor invasion, lymph node metastasis, distant metastasis, peritoneal dissemination, or TNM stage. 9 Werner et al 40 reported that a combination of five autoantibodies to MAGEA4, CTAG1, TP53, ERBB2_C and SDCCAG8 could detect 32% of GC patients at a specificity of 87%, and also showed no difference between early stage and late stage.
Zayakin et al reported that a 45-autoantibody signature could discriminate GC and healthy controls with AUC of 0.79 (59% sensitivity and 90% specificity) and could detect early GC with equal sensitivity as advanced GC (however, the P-value they showed was 0.09). 41 Meistere et al 42 accordance with this study. Another study also reported that TAA can be used as monitors of therapeutic response. 43 For a patient whose specific anti-TAA antibody has been detected, changes in antibody levels might reflect change in tumor status or tumor burden related to therapy. 7 Shimada 44 reviewed all studies of p53-Ab titers in esophageal squamous cell carcinoma (ESCC) and reported that p53-Ab is a useful molecular target both in the diagnosis and in the treatment of ESCC. Our previous study observed that the titer of anti-NPM1 antibody significantly increased in prostate cancer sera after surgical treatment, 45 which might reflect the autoimmune responses to the removal of tumor after cancer resection. Thereby, in the present study, we observed the temporal change of 14 antibodies in 67 sera from 25 GAC patients before and after resection. The results showed that 10 from 14 antibodies were significantly higher in GAC patients after surgery than before surgery, which was consist with the previous results. 45 In addition, another four antibodies (cyclin B1, p53, p16, MDM2)
showed no difference. However, Shimada et al 46 followed up 110 patients with esophageal carcinoma before and 1 month after surgery, and reported that p53-Abs titer generally decreased after surgery. They also followed up a 68-year old male patient with GAC for 5 years and observed that the p53-Ab titer decreased after surgery and finally converted from positive to negative at 31 months postoperatively, 47 which is different from our results.
This may be caused by the different cutoff values and the small sample size and short follow-up time (10 months) of our study.
The specific mechanism of the increased antibody titer after surgery is not completely clear. It is likely that patients with largesized tumor are frequently immunosuppressed, and the surgical removal of the tumor could reverse immune suppression owing to the reduction of the quantity of tumor-related immunosuppression factors, thereby allowing immune response to recover in the absence of the inhibitory cytokines. 45, 48 A few studies also assessed immunosuppression after primary tumor removal in humans and reported at least partial recovery of immune function following tumor resection. 49, 50 In summary, our study showed that the panel of nine TAA could enhance the detection of GAC regardless of tumor stage, tumor size, differentiation and lymph node metastasis. In addition, antibodies to antigens may be potential prognostic biomarkers. Further prospective studies with comprehensive follow-up information on GAC patients before and after resection may determine how potential antibodies predict GAC clinical outcome after resection. 
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